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Neisseria gonorrhoeae infections in the oro-pharynx: should we be routinely testing women? 
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Oropharyngeal infection with Neisseria gonorrhoeae is important: it is harder to treat than 
anogenital infection and the oro-pharynx provides a niche for the development of antimicrobial 
resistance (AMR).1 Additionally, as it is usually asymptomatic it can easily remain undetected, 
providing a reservoir of infection facilitating onward transmission. Emerging evidence suggests that 
in addition to oral sex, oropharyngeal infection may be transmitted by kissing.2 
The prevalence of oropharyngeal N gonorrhoeae in men who have sex with men (MSM) is estimated 
to be 5-10%,3,4 but there is limited evidence on the burden of extra-genital infection in 
heterosexuals. Whilst it is generally agreed that MSM should be routinely screened for 
oropharyngeal infection, there is no consensus for screening women, even though they may be at 
risk.5 Currently, national sexually transmitted infection (STI) testing guidelines in most countries do 
not recommend that women are routinely screened at the oropharyngeal site. Van Liere’s study in 
the Lancet Infectious Diseases is therefore a welcome addition to a scarce evidence base for 
informing testing guidelines. 
Van Liere and colleagues used ten years of Dutch STI surveillance data to explore optimal testing 
strategies for the detection of oropharyngeal N gonorrhoeae in women. They compared the 
prevalence of oropharyngeal N gonorrhoeae in clinics which routinely screened all women 
(‘universal testing’) with clinics who tested only based on behaviour or risk group (‘selective testing’) 
and found a test positivity of 1.4% in both groups. By extrapolating the positivity found in universal 
testing clinics to all selective testing clinics, weighted for case mix characteristics, they estimated 
that selective testing missed 70% of oropharyngeal infections, and importantly, half of 
oropharyngeal-only infections. The latter group is particularly concerning as they would not be 
incidentally treated as part of treatment for a concurrent genital infection.  
Amongst those in the universally tested group, independent risk factors for oropharyngeal infection 
were found to be sex work, being notified as a contact of an STI, and concurrent anogenital N 
gonorrhoeae infection. A testing strategy targeting those notified for an STI and reporting sex work 
was estimated to identify just over half of oropharyngeal infections. Testing those reporting oral sex 
would require almost all women (93%) to be tested and would still miss 6% of infections. 
This is a unique study which benefits from using a large national surveillance dataset. However, the 
findings of this study may not be generalisable to other clinical settings and countries. In the 
Netherlands, women attending STI clinics are likely at high-risk of N gonorrhoeae infection: over 10% 
were sex workers or swingers. Two thirds of N gonorrhoeae infection in the Netherlands is in fact 
diagnosed in primary care, which sees a considerably lower risk population. This is in contrast with 
the United Kingdom (UK), for example, where almost all gonorrhoea cases are diagnosed in STI 
clinics; thus, the risk profiles of women attending Dutch and UK STI clinics likely differ. Some caution 
may also be needed when using surveillance datasets for analysing less common events as coding 
errors can have a disproportionate influence on analysis outcomes in these circumstances.  
Clearly, universal screening will identify all infections. The authors do, however, acknowledge that 
this approach may not be cost-effective given the low prevalence of oropharyngeal infection in 
women, which is significantly lower than that seen in MSM. They also highlight the increased risk of 
false positive test results due to low positive predictive values when screening for a rare infection.6,7 
This is particularly true for pharyngeal samples where cross-reactivity with commensal Neisseria 
species may occur. Although all testing was performed by accredited laboratories, it is unclear 
whether confirmatory NAAT testing to minimise false positive results was performed.  
Despite these caveats, this study contributes significantly towards answering a difficult public health 
question.  It should encourage and inform further studies to determine optimal and cost-effective 
testing strategies for detecting oropharyngeal N gonorrhoeae infection in women to improve 
infection control and minimise the development of AMR.  
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